

TO OUR STAKEHOLDERS

Gastro Intestinal Cancer Institute NZ

PO Box 28 723

Remuera

Auckland 1541

Tel 0800 112 775

www.gicinz.org.nz



ANNUAL REPORT

FY 2014-2015

The Gastro-Intestinal Cancer Institute of New Zealand (GICI) is dedicated to improving the outcomes for patients with gastro-intestinal cancer. GICI aims to increase awareness of GI cancers and raise funds to support clinical research in New Zealand, focusing particularly on clinical trials.

TO OUR STAKEHOLDERS

CHAIR'S REPORT

Over the last year we have significantly lifted our profile in the community through increased social media engagement and fundraising events. I would like to thank Lexie McGuire, Executive Officer, for her efforts along with key board members in the development of our new education and awareness campaign. The website now has a modern and engaging format and our facebook page has reached 1,700 likes! Thanks to Novartis for assisting with a grant to make our website happen.

Events continue to be the highlight in our fundraising with GastroFest once again turning into an amazing event raising \$70,000 on the night.

In 2014, GICI began funding the A La CaRT study and completed the SCOT trial. We have two further research applications in progress for funding.

The very sad passing of Paul Hargreaves in August 2014 left a huge gap in the organisation. We will miss his passion and desire to help others.

I would like to personally acknowledge all of the GICI board, the Scientific Advisory Committee and Lexie McGuire for their excellent efforts this year. To all who have donated and supported us we thank you and look forward to working with you over the next year.



Grant Baker

TO OUR STAKEHOLDERS

STRATEGIC HIGHLIGHTS

GICI NZ has concentrated on the development of a marketing and fundraising plan to enable improved awareness with a subsequent increase in funds for promotion and scientific research into GI cancer treatment. The key components for implementation in the next year will be:

- Build GICI Profile through an Awareness Campaign
- Develop Peer-to-Peer Fundraising Campaign “Get Gutsy for GICI”
- Pursue Corporate Sponsorship
- Increase In Memory and Bequest Giving



We now have a presence on [Everyday Hero](#). People can create their own page and run for us, climb a mountain or cycle their way around a country. Become a ‘Gut Buster’ by getting Gutsy for GICI!!

ASK THE EXPERTS



The first, the Ask the Experts night, was a free information session that offered guests the opportunity to ask questions of GI cancer specialists and survivors. The event is a chance for us to engage with the community, in addition to our normal focus on raising awareness and funding research. We will continue to keep the event on our annual calendar.

TO OUR STAKEHOLDERS

SCIENTIFIC ADVISORY COMMITTEE

The Scientific Advisory Committee (SAC) offers advice to the GICI Board about clinical research into gastrointestinal cancers, and also provides guidance on all clinical matters for GICI. Our focus is on the entire gastrointestinal tract, so the SAC searches for studies relevant for New Zealand in an effort to support them when they might not otherwise be funded. This increases opportunities for patients to participate in trials of new therapies, and gain from them.

The SAC members have a broad experience between them in addition to their oncology expertise, with Professor Michael Findlay (Director Cancer Trials New Zealand, University links), Dr Chris Wynne (Phase I trials), Clare Walls (nutrition), Kerin Thompson (clinical trials), John McCall and Bridget Robinson (both with University research groups). In late 2014, the SCOT trial GICI supported reached its targeted numbers of patients, and we await the results. This compared 3 with the standard 6 months of chemotherapy for node-positive bowel cancer. During this year, GICI also supported the surgical A La Cart study comparing laparoscopic surgery for rectal cancer with standard anterior resection. Both trials were carried out as a collaboration with the Australasian Gastro-Intestinal Study Group (AGITG). The results will have a big impact over numbers of cycles of nerve-toxic chemotherapy and answer whether the move to laparoscopic surgery is as effective and better tolerated, respectively.



Bridget Robertson

Scientific Advisory Committee Chairperson

TO OUR STAKEHOLDERS

FUNDRAISING



On 6 November, we welcomed 200 guests to GastroFest at the Nathan Club, a charming venue located in a heritage building in downtown Auckland. We sought to create an event that is “not your typical charity dinner,” and designed it to be dynamic and interactive. Each course was prepared by a different acclaimed chef, and was paired with wine and beer matches. TV personality Carly Flynn was master of ceremonies and ensured that the night ran smoothly. Chef Geoff Scott dreamed up an elaborate interactive dining experience for the dinner’s main course. Guests were invited to participate in a lively auction with prizes that included a trip to Italy with a private tour of the Ferrari Factory, a signed Richie McCaw All Blacks jersey, and a luxurious golf holiday in Queenstown.

We're thrilled to report that we tripled last year's fundraising outcome and raised \$70,000 to go toward our goals of improving GI cancer outcomes. A big thank you to all of the people and businesses who helped.





IN MEMORY OF PAUL HARGREAVES

On 14 August, Paul Hargreaves, the inaugural Chairman of GICI, passed away unexpectedly from a stroke. Paul helped to found GICI in 2009 after being approached by his former oncologist, Mike Findlay, who hoped to start a charity that could help to fill the funding gap for gastro-intestinal clinical research. Paul had been diagnosed with terminal pancreatic cancer in 2006, and in a last-ditch effort had begun a treatment routine that was the result of an Italian clinical trial. Amazingly, Paul's cancer responded to the treatment and he recovered and lived the rest of his life cancer free.

Paul became devoted to raising awareness about gastro-intestinal cancer and helping GICI to become a leading funder of clinical research. With his considerable experience as an entrepreneur and director, Paul skilfully guided GICI through its start-up phase, an incredibly difficult feat. He enthusiastically championed the cause and shared his story and advice with scores of patients and families who sought his help.

I met Paul in April of 2013 when I became Executive Officer of GICI. Paul immediately took me under his wing and became a much-admired mentor. Not only did I respect Paul's passion and professional accomplishments, but I was amazed by his optimistic outlook and capacity for kindness. He radiated a kind of buoyancy and tranquillity that was appreciated by all who knew him. He had a warm and generous spirit and I feel exceptionally grateful to have worked with him.

Lexie McGuire

Previous Executive Officer

TO OUR STAKEHOLDERS

FINANCIAL HIGHLIGHTS

The fundraising income through events and donations remains very positive. Overall we are in a financially stable situation with funds invested.

OPERATING HIGHLIGHTS

Funds have been distributed towards research trials, however this has not been at the rate expected. The number of participants willing to participate in New Zealand trials dictates the use of the funds. Overheads remain very low with donated office thanks to Business Bakery and donation of services from Price Waterhouse Cooper.

LOOKING AHEAD

We are working towards increasing 'peer to peer' funding through the Everyday Hero website, as well as raising funds in [memoriam and through bequests](#) ([click here to go to the website](#)).

The positioning of research funds with an Endowment fund is a priority for 2015-2016. This will also place the organisation in a stronger position for grants through estate distributions. We will recommence grant applications in light of the rise in bowel cancer and GICI's profile. We are planning to access \$100K within the next financial year from grant funding.

The following accounts provide a statement of financial performance and the statement of financial position for 2014-2015. A full set of accounts are available on request.

Ruth Davy

Executive Officer

September 9, 2015

GI CANCER INSTITUTE (NZ) LIMITED ANNUAL REPORT

FOR THE YEAR ENDED 31 MARCH 2015

GI CANCER INSTITUTE (NZ) LIMITED STATEMENT OF FINANCIAL PERFORMANCE FOR THE YEAR ENDED 31 MARCH 2015

	Notes	2015 \$	2014 \$
Revenue			
Donations Received		98,724	181,090
Interest Received		3,590	1,226
Grant Income		5,783	9,217
Event Income		33,180	13,339
Total Revenue		141,277	204,872
Administration & Operations Expenses	5		
ACC		220	-
Bank Charges		829	1,456
Computer & IT		338	399
Conference Expenses		132	870
Design Fees		626	400
Event Expenses		11,116	5,266
Executive Officer Services		80,400	52,150
Fundraising Institute Membership		1,003	-
General Expenses		273	234
Printing, Stamps & Stationery		148	376
Telephone, Tolls & Internet		524	608
Loss on Disposal of Assets		-	1,456
Depreciation & Amortisation		4,914	2,086
Total Administration & Operations Expenses		100,523	65,301
Clinical Trials		7,826	11,739
Total Expenses		108,349	77,040
NET SURPLUS		32,928	127,832
SHAREHOLDER FUNDS AT START OF PERIOD		146,515	18,683
SHAREHOLDER FUNDS AT END OF PERIOD		179,443	146,515

GI CANCER INSTITUTE (NZ) LIMITED STATEMENT OF FINANCIAL POSITION AS AT 31 MARCH 2015

	Notes	2015 \$	2014 \$
Current Assets			
Bank		184,740	143,860
Trade and Other Receivables		3,725	6,200
Taxation		1,952	951
Total Current Assets		190,417	151,011
Non-Current Assets			
Tangible Assets	6	315	630
Intangible Assets	7	4,600	9,200
Total Non-Current Assets		4,915	9,830
Total Assets		195,332	160,841
Current Liabilities			
Trade Creditors and Accruals		8,030	13,377
Goods & Services Tax		3,159	427
Deferred Income		4,700	522
Total Liabilities		15,889	14,326
NET ASSETS		179,443	146,515
Represented by;			
Shareholder Funds		160	160
Issued Capital			
Uncalled Capital		(160)	(160)
Share Capital		-	-
Retained Earnings		179,443	146,515
TOTAL SHAREHOLDER FUNDS		179,443	146,515

TO OUR STAKEHOLDERS

CONTACT INFORMATION

RUTH DAVY EXECUTIVE OFFICER	GRANT BAKER CHAIRPERSON
	
Tel 027 273 7033 rdavy@gicin.z.org.nz	Tel 021 729 800 grant@gbaker.co.nz

ORGANISATIONAL INFORMATION

CC Number: 39174

Gastro Intestinal Cancer Institute NZ
PO Box 28723, Remuera, Auckland 1541, New Zealand
Tel 0800 112 775
www.gicin.z.org.nz

